

Molecular in vitro diagnostic examinations -
Requirements and recommendations for
pre-examination processes for urine and other body
fluids - Isolated cell-free DNA (ISO 18704:2026)

EESTI STANDARDI EESSÕNA

NATIONAL FOREWORD

<p>See Eesti standard EVS-EN ISO 18704:2026 sisaldab Euroopa standardi EN ISO 18704:2026 ingliskeelset teksti.</p> <p>Standard on jõustunud sellekohase teate avaldamisega EVS Teatajas.</p> <p>Euroopa standardimisorganisatsioonid on teinud Euroopa standardi rahvuslikele liikmetele kättesaadavaks 25.02.2026.</p> <p>Standard on kättesaadav Eesti Standardimis- ja Akrediteerimiskeskusest.</p>	<p>This Estonian standard EVS-EN ISO 18704:2026 consists of the English text of the European standard EN ISO 18704:2026.</p> <p>This standard has been endorsed with a notification published in the official bulletin of the Estonian Centre for Standardisation and Accreditation.</p> <p>Date of Availability of the European standard is 25.02.2026.</p> <p>The standard is available from the Estonian Centre for Standardisation and Accreditation.</p>
--	---

Tagasisidet standardi sisu kohta on võimalik edastada, kasutades EVS-i veebilehel asuvat tagasiside vormi või saates e-kirja meiliaadressile standardiosakond@evs.ee.

ICS 11.100.10

<p>Standardite ja standardilaadsete dokumentide reprodutseerimise ja levitamise õigus kuulub Eesti Standardimis- ja Akrediteerimiskeskusele</p> <p>Eesti standardid ja standardilaadsed dokumendid on Eesti Standardimis- ja Akrediteerimiskeskuse intellektuaalomand ning neid kasutatakse litsentsi alusel dokumentide kasutuslepingu tingimuste kohaselt.</p> <p>Ilma Eesti Standardimis- ja Akrediteerimiskeskuse eelneva kirjaliku loata on keelatud standardite ja standardilaadsete dokumentide täielik või osaline reprodutseerimine, levitamine, muutmine või kasutamine mis tahes kujul ja viisil - sealhulgas kopeerimine, skaneerimine, salvestamine või jagamine teel digiplatvormidel (k.a masinõppe ja tehisintellekti rakendustes). Loata kasutamine väljaspool litsentsi tingimusi käsitletakse õigusrikkumisena.</p> <p>Kui Teil on küsimusi standardite ja standardilaadsete dokumentide autoriõiguse kaitse kohta, võtke palun ühendust Eesti Standardimis- ja Akrediteerimiskeskusega: Veebileht www.evs.ee; telefon +372 6055050; e-post info@evs.ee</p> <p>The right to reproduce and distribute standards and standard-like documents belongs to the Estonian Centre for Standardisation and Accreditation</p> <p>Estonian standards and standard-like documents are the intellectual property of the Estonian Centre for Standardisation and Accreditation and are made available under license in accordance with the terms and conditions of the document use agreement.</p> <p>Without the prior written permission of the Estonian Centre for Standardisation and Accreditation, the full or partial reproduction, distribution, modification, or use of standards and standard-like documents in any form or by any means - including photocopying, scanning, storing, or sharing via digital platforms (incl. in machine learning and artificial intelligence applications) - is strictly prohibited. Any unauthorized use beyond the scope of the granted license is prohibited and may result in legal action.</p> <p>If you have any questions about copyright, please contact Estonian Centre for Standardisation and Accreditation: Homepage www.evs.ee; phone +372 605 5050; e-mail info@evs.ee</p>
--

EUROPEAN STANDARD

EN ISO 18704

NORME EUROPÉENNE

EUROPÄISCHE NORM

February 2026

ICS 11.100.10

Supersedes CEN/TS 17811:2022

English Version

Molecular in vitro diagnostic examinations - Requirements and recommendations for pre-examination processes for urine and other body fluids - Isolated cell-free DNA (ISO 18704:2026)

Analyses de diagnostic moléculaire in vitro - Exigences et recommandations relatives aux processus préanalytiques pour l'urine et d'autres liquides corporels - ADN libre extrait (ISO 18704:2026)

Molekularanalytische in-vitro-diagnostische Verfahren - Spezifikationen für präanalytische Prozesse für Urin und andere Körperflüssigkeiten - Isolierte zellfreie DNA (ISO 18704:2026)

This European Standard was approved by CEN on 13 February 2026.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels

European foreword

This document (EN ISO 18704:2026) has been prepared by Technical Committee ISO/TC 212 "Medical laboratories and in vitro diagnostic systems" in collaboration with Technical Committee CEN/TC 140 "In vitro diagnostic medical devices" the secretariat of which is held by DIN.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by August 2026, and conflicting national standards shall be withdrawn at the latest by February 2029.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN shall not be held responsible for identifying any or all such patent rights.

This document supersedes CEN/TS 17811:2022.

Any feedback and questions on this document should be directed to the users' national standards body/national committee. A complete listing of these bodies can be found on the CEN website.

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and the United Kingdom.

Endorsement notice

The text of ISO 18704:2026 has been approved by CEN as EN ISO 18704:2026 without any modification.



**International
Standard**

ISO 18704

**Molecular in vitro diagnostic
examinations — Requirements
and recommendations for pre-
examination processes for urine
and other body fluids — Isolated
cell-free DNA**

*Analyses de diagnostic moléculaire in vitro — Exigences et
recommandations relatives aux processus préanalytiques pour
l'urine et d'autres liquides corporels — ADN libre extrait*

**First edition
2026-02**

This document is a preview generated by EVS



COPYRIGHT PROTECTED DOCUMENT

© ISO 2026

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

Contents

	Page
Foreword	iv
Introduction	v
1 Scope	1
2 Normative references	1
3 Terms and definitions	1
4 General requirements	6
5 Outside the laboratory	7
5.1 Specimen collection.....	7
5.1.1 Information about the patient or specimen donor.....	7
5.1.2 Selection of the body fluid collection device by the laboratory.....	7
5.1.3 Urine and other body fluid specimen collection from the patient or donor and stabilization procedures.....	8
5.1.4 Information about the specimen storage requirements at the body fluid collection facility.....	9
5.2 Transport requirements.....	11
5.2.1 General.....	11
5.2.2 Transport using urine and other body fluid collection devices with cfDNA stabilizers.....	11
5.2.3 Transport using urine and other body fluid collection devices without cfDNA stabilizers.....	12
6 Inside the laboratory	12
6.1 Specimen or sample reception.....	12
6.2 Specimen or sample storage after transport and reception.....	12
6.3 Urine and other body fluid specimen or sample processing prior to cfDNA isolation.....	13
6.4 Storage requirements for urine and other body fluid samples after processing.....	13
6.5 Isolation of urine and other body fluid cfDNA.....	14
6.5.1 General.....	14
6.5.2 Using a commercial cfDNA isolation kit approved for diagnostic use.....	14
6.5.3 Using a laboratory developed cfDNA isolation procedure.....	14
6.6 Quantity and quality assessment of isolated cfDNA.....	15
6.6.1 General.....	15
6.6.2 Quantity assessment of cfDNA.....	15
6.6.3 Quality assessment of cfDNA.....	15
6.7 Storage of isolated urine and other body fluid cfDNA.....	16
6.7.1 General.....	16
6.7.2 Storage of isolated urine and other body fluid cfDNA, isolated with a commercially available kit.....	16
6.7.3 Storage of isolated urine and other body fluid cfDNA, isolated with the laboratory's own procedure.....	17
Annex A (informative) Effects of pre-examination storage of unstabilized urine on cfDNA	18
Annex B (informative) Effects of pre-examination storage of unstabilized and stabilized urine on the amount of a specific cfDNA target sequence	22
Bibliography	24

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

ISO draws attention to the possibility that the implementation of this document may involve the use of (a) patent(s). ISO takes no position concerning the evidence, validity or applicability of any claimed patent rights in respect thereof. As of the date of publication of this document, ISO had not received notice of (a) patent(s) which may be required to implement this document. However, implementers are cautioned that this may not represent the latest information, which may be obtained from the patent database available at www.iso.org/patents. ISO shall not be held responsible for identifying any or all such patent rights.

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 212, *Medical laboratories and in vitro diagnostic systems*, in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 140, *In vitro diagnostic medical devices*, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

Molecular in vitro diagnostics has enabled significant progress in medicine. Further progress has been achieved and is still expected by new technologies used to examine profiles of nucleic acids, proteins, and metabolites in human tissues and body fluids (e.g. genomic, epigenomic, transcriptomic, proteomic and metabolomic profiling). However, the profiles of these molecules can change drastically during specimen collection, transport, storage and processing. This can make the outcome from diagnostics or research unreliable or even result in failure because the subsequent examination will not measure the genuine profile of nucleic acids, proteins or metabolites as it was in the patient, but a profile altered by the pre-examination process. Therefore, specifying, developing, verifying and validating preanalytical workflows has become an essential part of examination development.^[21]

Most of the DNA in the body is located within cells, but small amounts of DNA originating from cells can also be found outside of cells (extracellular DNA). In case of circulating body fluids such as blood, this DNA is called circulating cell-free DNA (ccfDNA) and in case of non-circulating body fluids such as urine, saliva, cerebrospinal fluid, pleural effusion, ascites, and synovial fluid, the DNA is called cell-free DNA (cfDNA). cfDNA is of specific interest, as for example cfDNA in urine originates from cells from the genitourinary tract or from ccfDNA passing through glomerular filtration.^[22] cfDNA from cancerous or malignant cells in urine have been associated with cancer specific sequences, epigenetic and structural changes.^{[23],[24]} Urine is currently the most frequently used non-circulating body fluid for cfDNA examination because it is easily obtained from patients. Although urine is often described as the major specimen type, in this document the term body fluid is used for urine and other body fluids as defined in [Clause 3](#).

Standardization of the entire workflow from specimen collection to the cfDNA examination is needed to minimize post-collection release of DNA from cells into the fluid and degradation of cfDNA in the specimen, which can change the original native cfDNA profile in the body fluid. Post collection microbial growth in the specimen can further enhance the degradation of the cfDNA, e.g. in urine and saliva. Furthermore, the isolation of cfDNA can lead to a cfDNA profile bias. Different methods to determine cfDNA yield and quality can lead to additional variations and impacts.

Studies have been undertaken to determine the pre-examination sources of these and other variables, as they can impact the cfDNA examination. The variables can compromise the specified examination performance characteristics, such as sensitivity, specificity, linearity and reproducibility. They can also impact the examination reliability which could lead to an erroneous examination result and misdiagnosis.

This document draws upon such work to codify and standardize the steps prior to cfDNA examination from body fluids in what is referred to as the pre-examination process.

In this document, the following verbal forms are used:

- “shall” indicates a requirement;
- “should” indicates a recommendation;
- “may” indicates a permission;
- “can” indicates a possibility or a capability.

Molecular in vitro diagnostic examinations — Requirements and recommendations for pre-examination processes for urine and other body fluids — Isolated cell-free DNA

1 Scope

This document specifies requirements and provides recommendations for the pre-examination process of cell-free DNA (cfDNA) from body fluid specimens other than blood, including but not limited to the collection, handling, storage, transport, processing and documentation of human body fluids, such as urine, pleural effusions, ascites, cerebrospinal fluid (CSF), and saliva, intended for cfDNA examination. Processing includes multiple steps, such as centrifugation for specimen purification and isolation of cfDNA.

This document does not cover dedicated measures for cytohistological analysis of nucleated cells derived from body fluid, nor measures for preserving and handling of pathogens, and other bacterial or whole microbiome DNA in body fluids described.

Dedicated measures for preserving circulating cell-free DNA (ccfDNA) from blood are covered in ISO 20186-3.

This document is applicable to medical laboratories, health institutions including facilities collecting and handling specimens, laboratory customers, in vitro diagnostic examination developers and manufacturers, biobanks, institutions and organizations performing biomedical research, and regulatory authorities.

NOTE International, national or regional regulations or requirements can also apply to specific topics covered in this document.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 15189, *Medical laboratories — Requirements for quality and competence*

ISO 13485, *Medical devices — Quality management systems — Requirements for regulatory purposes*

3 Terms and definitions

For the purposes of this document, the terms and definitions given in ISO 15189, ISO 13485 and the following apply.

ISO and IEC maintain terminology databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <https://www.iso.org/obp>
- IEC Electropedia: available at <https://www.electropedia.org/>

3.1 aliquot

portion of a larger amount of homogenous material, assumed to be taken with negligible sampling error

Note 1 to entry: The term is usually applied to fluids that are uniform in structure and composition. Tissues are heterogeneous and therefore cannot be aliquoted.